Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AstraZeneca | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: AstraZeneca

Loss of exclusivity for key brands wallops results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca

2Q Revenues: $6.7 billion (-21%)

2Q Earnings: $1.6 billion (-19%)

YTD Revenues: $14.0 billion (-16%)

YTD Earnings: $3.3 billion (-23%)

Comments: U.S. revenues were down 29%, with the loss of exclusivity for Seroquel IR accounting for 80% of the revenue decline. Revenue in the Rest of World (ROW) was down 12% in the quarter. Loss of exclusivity on several key brands accounted for 15% of the revenue decline in the quarter. Nexium sales were $949 million (-13% at CER). Seroquel sales were $647 million (-57% at CER). Seroquel IR sales were 277 million (-75% at CER). Crestor sales were 1.6 billion (-5% at CER). Atacand sales were $269 million (-25% at CER). Symbicort sales were $795 million (+3 at CER%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters